An ultra-high sensitivity dual-gated biosensor based on an MOS transistor, which is applicable to detection of a series of early tumors. The sensor is prepared and processed by using SOI wafers, and a unique dual-gated structure is realized by ion implantation technique. The sensor is prepared by an ultraviolet lithography combined with an NLD etching method, realizing trace, instant and marker-free detection of tumor markers. The method detects a change in capacitance in the channel during binding of antigen antibodies. The detection method involved in the invention is more stable and strong in anti-interference, can meet the demands in the aspect of detection range and sensitivity, and especially has extremely outstanding detection sensitivity, and can detect a sample with a lowest concentration in the range of 1 fg/ml1 ng/ml.

The present technology regards the utilization of CAECAM1 as a biomarker for cancer. In particular the present invention regards the detection and measurement of soluble CAECAM1 levels for the detection and diagnosis of melanoma.

Disclosed herein are methods of accurately measuring carcinoembryonic antigen in a biological sample and methods of identifying and treating a mucinous cyst in a subject.

The present technology regards the utilization of CEACAM1 as a biomarker for cancer. In particular the present invention regards the detection and measurement of soluble CEACAM1 levels for the detection and diagnosis of melanoma.

This disclosure provides, among other things, a method of sample analysis, that comprises: (a) binding target analytes to capture agents that are attached to a surface of a plate, wherein the plate comprises (i) a sensing amplification layer comprises nanostructures that enhance signals and (ii) the capture agents are attached to said sensing amplification layer; (b) reading the plate with a reading device to produce an image of signals that represent individual binding events; and (c) identifying and counting individual binding events in an area of the image, thereby providing an estimate of the amount of one or more analytes in the sample. A system for performing the method is also provided.

Provided is a biomarker for detecting colorectal cancer in an early stage. A colorectal cancer biomarker for detecting colorectal cancer, wherein the biomarker consists of at least one protein of the following 22 proteins with numbers 1 to 22, or at least one peptide of the partial peptides of the proteins with numbers 1 to 22: 1. Annexin A11; 2. Annexin A3; 3. Annexin A4; 4. Tanascin-N; 5. Transferrin receptor protein 1; 6. Glucose transporter 1; 7. Complement component C9; 8. CD88 antigen; 9. 78 kDa glucose-regulated protein; 10. -1-acid glycoprotein; 11. Matrix metalloproteinase-9; 12. Angiopoietin-1; 13. CD67 antigen; 14. Mucin-5B; 15. Adapter protein GRB2; 16. Annexin A5; 17. Olfactomedin-4; 18. Neutral amino acid transporter B(0); 19. Tripeptidyl-peptidase 1; 20. Heat shock-related 70 kDa protein 2; 21. Proteasome subunit type-5; or 22. Neutrophil gelatinase-associated lipocalin.

The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.

The present disclosure relates generally to detection of molecular biomarkers in a sample or diagnosis of a subject based upon detection or quantification of molecular biomarkers in a sample, specifically to the identification and use of biomarkers for pancreatic cysts.

The invention relates to methods and uses of a panel of biomarkers in a body fluid sample for diagnosing and/or monitoring lung cancer, in particular early stage lung cancer. The biomarkers include particular histone modifications present on cell free nucleosomes, in combination with Carcinoembryonic Antigen (CEA).

An ultra-high sensitivity dual-gated biosensor based on an MOS transistor, which is applicable to detection of a series of early tumors. The sensor is prepared and processed by using SOI wafers, and a unique dual-gated structure is realized by ion implantation technique. The sensor is prepared by an ultraviolet lithography combined with an NLD etching method, realizing trace, instant and marker-free detection of tumor markers. The method detects a change in capacitance in the channel during binding of antigen antibodies. The detection method involved in the invention is more stable and strong in anti-interference, can meet the demands in the aspect of detection range and sensitivity, and especially has extremely outstanding detection sensitivity, and can detect a sample with a lowest concentration in the range of 1 fg/ml1 ng/ml.